Demand and Revenue this year, Compassionate Use Program.
So today's news from Zacks said that INSM would pursue a compassionate use program for the second half of this year. Doesn't that indicate that there is some demand building for the product already and that those who have used it, or need it, want it?
My understanding is that with a compassionate use program, the drug still needs to be paid for and thus revenues will flow this year, earlier than many may have thought. Will it affect INSM PPS and financing options if they have $10 million in revenue this year even before any marketing approval?
No matter whether we begin having substantial revenue this year or next year, the time to buy Insmed based on that "hidden" gem is now. Zacks also said the data from CF was being released "soon." Quarter 2 surprise??? Very possible...